Literature DB >> 6151528

Comparative trial of two dose regimens of terfenadine in patients with hay fever.

J C Murphy-O'Connor, R L Renton, D M Westlake.   

Abstract

Eighty patients with hay fever took part in a double-blind study to compare the efficacy of two doses of terfenadine, namely 60 mg b.d., the standard recommended dose, and 120 mg b.d. Thirty-nine patients received 60 mg b.d. and thirty-eight received 120 mg b.d., each given over 1 week. Symptoms were assessed at the start and end of treatment and were also recorded in diary cards. Over-all efficacy was determined by doctor and patient at the end of treatment. Onset of relief of symptoms after the first dose was recorded. The results showed no significant differences between the two treatments. Symptom relief was good for both (54%-63% experiencing good or complete relief) and the target symptoms of hay fever (i.e. those most commonly reported) were relieved particularly well. Average onset of symptom relief was 72 minutes for 60 mg and 59 minutes for 120 mg. Side-effects were few for both doses, only three patients in total reporting sedation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6151528     DOI: 10.1177/030006058401200603

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  3 in total

Review 1.  Terfenadine. The first nonsedating antihistamine.

Authors:  H C Masheter
Journal:  Clin Rev Allergy       Date:  1993

Review 2.  Optimum pharmacological management of chronic rhinitis.

Authors:  F E Simons; K J Simons
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

Review 3.  Terfenadine. An updated review of its pharmacological properties and therapeutic efficacy.

Authors:  D McTavish; K L Goa; M Ferrill
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.